Your session is about to expire
← Back to Search
Monoclonal Antibodies
Quarterly Ranibizumab 0.5mg for Age-Related Macular Degeneration (PREVENT Trial)
Phase 1 & 2
Waitlist Available
Led By Maziar Lalezary, MD
Research Sponsored by Southern California Desert Retina Consultants, MC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
Summary
This study will determine whether quarterly injections of Ranibizumab may prevent eyes with dry age-related macular degeneration from progressing to wet age-related macular degeneration (AMD).
Eligible Conditions
- Age-Related Macular Degeneration
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Development of exudative AMD
Secondary study objectives
Baseline predictive factors
Development of geographic atrophy (GA)
Number of injections
+4 moreTrial Design
2Treatment groups
Active Control
Group I: Quarterly Ranibizumab 0.5mgActive Control1 Intervention
Quarterly intravitreal injection of 0.5mg ranibizumab
Group II: ShamActive Control1 Intervention
Sham Injection
Find a Location
Who is running the clinical trial?
Southern California Desert Retina Consultants, MCLead Sponsor
1 Previous Clinical Trials
40 Total Patients Enrolled
Maziar Lalezary, MDPrincipal InvestigatorSouthern California Desert Retina Consultants
1 Previous Clinical Trials
45 Total Patients Enrolled
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger